AU2021254262A1 - Methods for treatment of coronavirus infections - Google Patents

Methods for treatment of coronavirus infections Download PDF

Info

Publication number
AU2021254262A1
AU2021254262A1 AU2021254262A AU2021254262A AU2021254262A1 AU 2021254262 A1 AU2021254262 A1 AU 2021254262A1 AU 2021254262 A AU2021254262 A AU 2021254262A AU 2021254262 A AU2021254262 A AU 2021254262A AU 2021254262 A1 AU2021254262 A1 AU 2021254262A1
Authority
AU
Australia
Prior art keywords
cov
sars
subject
probenecid
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021254262A
Other languages
English (en)
Inventor
Robert Jeff Hogan
Jackelyn Murray
Ralph A. Tripp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Georgia Research Foundation Inc
Original Assignee
University of Georgia
University of Georgia Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/875,487 external-priority patent/US11116737B1/en
Application filed by University of Georgia, University of Georgia Research Foundation Inc filed Critical University of Georgia
Publication of AU2021254262A1 publication Critical patent/AU2021254262A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2021254262A 2020-04-10 2021-04-09 Methods for treatment of coronavirus infections Pending AU2021254262A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202063008624P 2020-04-10 2020-04-10
US63/008,624 2020-04-10
US202063023021P 2020-05-11 2020-05-11
US63/023,021 2020-05-11
US16/875,487 2020-05-15
US16/875,487 US11116737B1 (en) 2020-04-10 2020-05-15 Methods of using probenecid for treatment of coronavirus infections
EP20202059.0 2020-10-15
EP20202059.0A EP3892269B1 (en) 2020-04-10 2020-10-15 Probenecid for treating coronavirus infections
US202163151551P 2021-02-19 2021-02-19
US63/151,551 2021-02-19
PCT/US2021/026588 WO2021207606A1 (en) 2020-04-10 2021-04-09 Methods for treatment of coronavirus infections

Publications (1)

Publication Number Publication Date
AU2021254262A1 true AU2021254262A1 (en) 2022-11-03

Family

ID=78023981

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021254262A Pending AU2021254262A1 (en) 2020-04-10 2021-04-09 Methods for treatment of coronavirus infections

Country Status (5)

Country Link
EP (1) EP4132503B1 (https=)
JP (1) JP7840570B2 (https=)
CN (1) CN116075298B (https=)
AU (1) AU2021254262A1 (https=)
WO (1) WO2021207606A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4157288A2 (en) * 2020-06-02 2023-04-05 Institut Gustave-Roussy Modulators of purinergic receptors and related immune checkpoint for treating acute respiratory distress syndrom
JP2024529291A (ja) * 2021-07-06 2024-08-06 ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド ウイルス感染症の処置および予防のための組成物および方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005005596A2 (en) * 2003-06-18 2005-01-20 Chinese National Human Genome Center At Shanghai Characterization of the earliest stages of the severe acute respiratory syndrome (sars) virus and uses thereof
MX341050B (es) * 2010-04-07 2016-08-05 Celgene Corp * Metodos para tratar infeccion viral respiratoria.
US20130280806A1 (en) * 2010-05-17 2013-10-24 Donald Rubin Mammalian genes involved in infection
US11554112B2 (en) * 2018-06-07 2023-01-17 Herum Therapeutics International Limited Combinations of β-lactam compounds and probenecid and uses thereof
CN111601618A (zh) * 2018-09-14 2020-08-28 江阴贝瑞森制药有限公司 孟鲁司特与肽的新缀合物
EA202193251A1 (ru) * 2019-06-05 2022-03-10 Эмори Юниверсити Пептидомиметики для лечения коронавирусной и пикорнавирусной инфекций

Also Published As

Publication number Publication date
EP4132503A4 (en) 2024-02-14
EP4132503A1 (en) 2023-02-15
JP7840570B2 (ja) 2026-04-06
WO2021207606A1 (en) 2021-10-14
CA3173187A1 (en) 2021-10-14
CN116075298B (zh) 2026-03-20
CN116075298A (zh) 2023-05-05
EP4132503B1 (en) 2026-04-22
JP2023520929A (ja) 2023-05-22

Similar Documents

Publication Publication Date Title
EP3892269B1 (en) Probenecid for treating coronavirus infections
US20210361688A1 (en) System, method and use of a certain medication for reducing viral replication in the airways mucosae
CN113244212B (zh) 黄芩素在制备预防和/或治疗新型冠状病毒感染疾病的药物中的应用
US11364227B2 (en) Sphingosine kinase 2 inhibitor for treating coronavirus infection
KR102910416B1 (ko) 유행성 rna 바이러스 감염질환의 예방 또는 치료용 약제학적 조성물
WO2021151264A1 (zh) 酰基化螺旋霉素在制备治疗冠状病毒感染疾病药物上的应用
JP2023520323A (ja) ２型アンギオテンシンｉｉ受容体アゴニストの新規使用
EP4132503B1 (en) Probenecid for use in the treatment of sars-co-v2 infections
JP2023526754A (ja) Ｃｏｖｉｄ および ｃｏｖｉｄ－１９ の予防と治療の方法
Latarissa et al. Efficacy of quinine sulfate in patients with mild-to-moderate COVID-19: A randomized controlled trial
CA3173187C (en) Methods for treatment of coronavirus infections
KR20230021009A (ko) 항바이러스 치료로서의 아젤라스틴
US20240327339A1 (en) Compositions and methods for treating and preventing viral infections
US20230030607A1 (en) Novel oxygen pulse therapy method for treating COVID19 and viral, bacterial, fungal or parasitic respiratory and other diseases
US11471448B2 (en) Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia
US20240307487A1 (en) Compositions of anti-viral peptides and/or compounds and methods of use thereof
Hassan Presentation, management and pathogenesis of the SARS-CoV-2 in Children
JP2025527908A (ja) 気道感染症を処置するための医薬乾燥粉末組成物および方法
CN114432305A (zh) Cay10603在制备预防和治疗冠状病毒的药物中的应用